High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients by Wake, RM et al.
 © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of 
America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 
Title: High Cryptococcal Antigen Titers in Blood are Predictive of 
Subclinical Cryptococcal Meningitis Among HIV-Infected Patients 
 
Rachel M Wake 
Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for 
Communicable Diseases, Johannesburg, South Africa; Institute for Infection and Immunity, St. George’s 
University of London, London, UK 
Corresponding author: Mycology Reference Laboratory, NICD, 1 Modderfontein Road, Johannesburg, 
2131, South Africa; 0115550323; rmwake@gmail.com 
 
Erika Britz 
Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for 
Communicable Diseases, Johannesburg, South Africa 
 
Charlotte Sriruttan 
Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for 
Communicable Diseases, Johannesburg, South Africa; Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, South Africa 
 
Ivy Rukasha 
Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for 
Communicable Diseases, Johannesburg, South Africa 
 
Tanvier Omar 
Department of Anatomical Pathology, University of the Witwatersrand 
 
David C Spencer 
Helen Joseph Hospital, Johannesburg, South Africa 
 
Jeremy S Nel 
Helen Joseph Hospital, Johannesburg, South A99frica 
 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/cix872/4349512
by St George's University of London user
on 28 November 2017
 2 
 
Sello Mashamaite 
Right to Care, Johannesburg, South Africa 
 
Adeboye Adelekan 
Centers for Disease Control and Prevention, Pretoria, South Africa 
 
Tom M Chiller 
Centers for Disease Control and Prevention, Atlanta, GA, USA 
 
Joseph N Jarvis 
Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene 
and Tropical Medicine, London, UK; Botswana-UPenn Partnership, Gaborone, Botswana; Division of 
Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 
Philadelphia, Pennsylvania, USA 
 
Thomas S Harrison 
Institute for Infection and Immunity, St. George’s University of London, London, UK; St George’s Hospital, 
London, UK 
 
Nelesh P Govender 
Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for 
Communicable Diseases, Johannesburg, South Africa; School of Pathology, University of the 
Witwatersrand, Johannesburg, South Africa; Division of Medical Microbiology, University of Cape Town, 
South Africa; University of Cape Town, South Africa 
 
 
 
Running title: Blood Cryptococcal Antigen Titers   
 
 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/cix872/4349512
by St George's University of London user
on 28 November 2017
 3 
 
Summary: Blood cryptococcal antigen (CrAg) titers are associated with concurrent 
subclinical cryptococcal meningitis in at least a third of CrAg-positive patients with advanced 
HIV, which may contribute to increased mortality. Blood CrAg titers can guide management 
in this population.  
 
 
Abstract 
Background 
High mortality rates among asymptomatic cryptococcal antigen (CrAg)-positive patients 
identified through CrAg screening, despite pre-emptive fluconazole, may be due to undiagnosed 
cryptococcal meningitis. 
 
Methods 
Symptoms were reviewed in CrAg-positive patients identified through screening 19,233 
individuals with CD4 cell counts < 100 cells/µL at 17 clinics and 3 hospitals in Johannesburg 
from September 2012 until September 2015, and 2 of these hospitals until June 2016. 
Cerebrospinal fluid from 90/254 (35%) asymptomatic patients and 78/173 (45%) with 
headache only was analyzed for cryptococcal meningitis, present if Cryptococcus was identified 
by India ink microscopy, culture, or CrAg test. CrAg titers were determined on stored blood 
samples from 62 of these patients. The associations between blood CrAg titer, concurrent 
cryptococcal meningitis, and mortality were assessed. 
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Results 
Cryptococcal meningitis was confirmed in 34% (95% confidence interval (CI) 25%-43%, 
n=31/90) of asymptomatic CrAg-positive patients and 90%, (95% CI 81%-96%, n=70/78) with 
headache only. 
 
Blood CrAg titer was significantly associated with concurrent cryptococcal meningitis in 
asymptomatic patients (p<0.001) and patients with headache only (p=0.003). The optimal titer 
for predicting cryptococcal meningitis was >160 (sensitivity 88.2%, specificity 82.1%); odds 
ratio for concurrent cryptococcal meningitis 34.5 (95% CI 8.3-143.1, p<0.001). 
 
Conclusions  
Around a third of asymptomatic CrAg-positive patients have concurrent cryptococcal 
meningitis. More effective clinical assessment strategies and antifungal regimens are required 
for CrAg-positive patients, including investigation for cryptococcal meningitis irrespective of 
symptoms. Where not possible to perform LPs on all CrAg-positive patients, blood CrAg titers 
should be used to target those most at risk of cryptococcal meningitis. 
 
 
Keywords: Meningitis, Cryptococcal; Cryptococcosis; Diagnosis; Mass screening; Mortality 
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Background 
Cryptococcal antigenemia is strongly predictive of subsequent cryptococcal meningitis in HIV-
infected adults with CD4+ T-lymphocyte (CD4) counts of <100 cells/µL(1,2). This forms the 
basis of a ‘screen-and-treat’ approach to early detection, whereby HIV-infected patients with a 
CD4 count of <100 cells/µL are tested for cryptococcal antigen (CrAg) in blood (whole blood, 
plasma, or serum) prior to commencing antiretroviral therapy (ART). If the CrAg test is positive, 
and patients have no signs or symptoms of meningitis, they are treated with a pre-emptive 
course of fluconazole; 800 mg daily for two weeks, followed by 400 mg for eight weeks and then 
200 mg pending immune reconstitution on ART. This strategy is included in World Health 
Organization (WHO) management guidelines for patients with advanced HIV (3–5), and adopted 
as recommended practice in several countries (6,7). However, the optimal management of 
patients who have cryptococcal antigenemia and do not have overt clinical evidence of 
meningitis is yet to be determined. 
  
Recent evidence suggests that the CrAg screen-and-treat approach reduces the incidence of 
subsequent cryptococcal meningitis and death (8–10). However, most studies have found a 
persistent and independent association between cryptococcal antigenemia and mortality, 
despite pre-emptive fluconazole therapy,(8–12) implying that CrAg-positive patients may not 
be adequately investigated and treated under current guidelines. 
 
A proportion of CrAg-positive patients may have meningeal infection with Cryptococcus without 
exhibiting any signs or symptoms, or complaining of a headache only(10,13). These cases of 
‘subclinical cryptococcal meningitis’ are likely to be under-recognised, since WHO guidelines do 
not specifically recommend lumbar punctures (LPs) among asymptomatic CrAg-positive 
patients(4), and where they are routinely offered, LP uptake is poor(9,10,14). Furthermore, 
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many resource-limited settings where CrAg screening is now being implemented do not have 
access to the required equipment or health-workers with the ability to carry out LPs at the 
screening site(15). 
 
Headache is a common and inconsistently reported complaint among patients with advanced 
HIV,(16–19) and prior studies have found having a headache to be a poor predictor of 
cryptococcal meningitis in CrAg-positive patients(10,19). Physicians therefore frequently omit 
to perform LPs if headache occurs without any other neurological signs or 
symptoms(9,10,14,17). 
 
Studies have shown an association between blood CrAg titer and the development of 
subsequent cryptococcal meningitis and/or mortality in CrAg-positive patients(1,11,19,20). 
However, the relationship between blood CrAg titer and concurrent cryptococcal meningitis has 
not yet been systematically investigated. We performed a cross-sectional study to establish a) 
the prevalence of subclinical and minimally symptomatic (patients with headache only) 
cryptococcal meningitis, and b) whether blood CrAg titer was predictive of concurrent 
cryptococcal meningitis in CrAg-positive individuals identified during routine screening, who 
were asymptomatic or complained of headache only, and who had an LP performed. A 
subsequent prospective cohort study assessed the relationship between CrAg titre and 
concurrent cryptococcal meningitis, with mortality within six months. 
  
Methods 
The studies were conducted at 17 primary care clinics and 3 hospitals in Johannesburg from 
September 2012 until September 2015, and at 2 of these hospitals: Helen Joseph and Tambo 
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Memorial Hospital until June 2016. Ethics approval was granted by the University of the 
Witwatersrand and the London School of Hygiene and Tropical Medicine; the study protocol 
was also cleared by the Centers for Disease Control and Prevention. All HIV-infected individuals 
presenting to these facilities during the study period with a CD4 count of <100 cells/µL had a 
qualitative CrAg test performed in the laboratory using a lateral flow assay (LFA, 
ImmunoMycologics, Norman, Oklahoma, USA) on remnant ethylene-diamine-tetraacetic acid 
(EDTA)-containing blood from the CD4 count sample. If CrAg-positive, individuals aged >16 
years were invited to participate in the study. If enrolled, information (including the presence of 
headache or confusion) was collected from them, or from their medical records, by professional 
study nurses using standardised structured questionnaires. CrAg-positive patients were 
managed by their usual health providers who received regular training on national guidelines 
for CrAg screening and treatment(6), delivered by study investigators. Recommended 
management was initial assessment for any symptoms or signs of meningitis and, if present, 
urgent referral for investigation of cryptococcal meningitis with LP and subsequent treatment 
as appropriate(6). If symptoms and signs of meningitis were absent, the guidelines suggested an 
LP should be considered ‘if available’. If an LP was not performed, or if it excluded a diagnosis of 
cryptococcal meningitis, a course of pre-emptive fluconazole for at least 12 months was 
recommended as per WHO guidance(4). 
 
We carried out a cross-sectional study to establish the prevalence (using exact binomial 
confidence intervals) of concurrent cryptococcal meningitis, and the relationship with blood 
CrAg titer, in participants with neither headache nor confusion, and those with headache only, 
who had an LP performed within a month of review of their CrAg test result. A sample size of 88 
and 62 participants was required to determine an estimated prevalence of concurrent 
cryptococcal meningitis of 35% and 80% in the asymptomatic and headache only groups 
respectively, with 10% precision. Concurrent cryptococcal meningitis was defined as occurring 
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in those who had Cryptococcus identified by cerebrospinal fluid (CSF) microscopy with India 
ink, fungal culture, and/or CSF CrAg testing.  
 
CrAg-positive whole blood samples were sent from the diagnostic facilities to the reference 
laboratory during the study period, and were stored at -70˚C. CrAg titer was determined using 
the CrAg LFA on serially-diluted samples of thawed unspun whole blood, using manufacturer’s 
instructions. Titers were read manually by three investigators, who were blinded to the CSF 
results and to each others’ readings. Serially-diluted blood samples were tested until the next 
reading was negative. If discordant, the higher reading was used as long as there was agreement 
within a double dilution.  
 
The association between blood CrAg titer and concurrent cryptococcal meningitis was tested 
using a Mann-Whitney U test for the ‘asymptomatic’, the ‘headache only’ and combined groups. 
A receiver operating characteristic curve was used to establish an optimal ‘cut-off’ titer that 
could be used to screen for concurrent cryptococcal meningitis, and the sensitivity and 
specificity of this titer was determined. The cut-off titer was then used to estimate the odds 
ratio of concurrent cryptococcal meningitis with a high blood CrAg titer and other variables 
were assessed for their association with cryptococcal meningitis. 
 
Prospective data on ART, antifungal treatment and mortality were obtained from clinic and 
phone-call follow-up and/or review of clinical and laboratory records for up to three years. 
Progression to death within six months in those with/without concurrent cryptococcal 
meningitis and with high/low blood CrAg titer was examined by Kaplan-Meier estimates and a 
multivariate Cox proportional hazards model. The following variables were considered 
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potential confounders: age, sex, baseline CD4 count, ART status, headache and whether or not 
patients received any antifungal therapy following LP. Assuming a 15% risk of death among 
those with a blood CrAg titer ≤160 (based on a previous study(20)), with a two-sided 
significance of 95% and power of 80%, a sample size of at least 120 individuals was required in 
each group to detect at least a 15% difference in mortality among those with blood CrAg titer 
>160. 
 
Results 
Of 19,233 HIV-infected patients over the age of 16 years with CD4 counts <100 cells/µL who 
were screened during the study period, 851 were CrAg-positive (4.4%, 95% CI 4.1% - 4.7%). 
Demographic and clinical data (Supplementary Table 1) including signs and symptoms of 
meningitis were available for 505 (59.3%) patients. Of these, 254 (50.3%, 95% CI 45.8 - 54.7%) 
reported no headache or confusion at the time of CrAg test, 173 (34.3%, 95% CI 30.1 - 38.6%) 
complained of a headache without any confusion, and 78 (15.4%, 95% CI 12.4% - 18.9%) were 
confused (see Figure 1). There were no significant differences in age (p=0.2), sex (p=0.5) or CD4 
cell count (p=0.3) among those groups with no symptoms, headache only or confusion 
(Supplementary Table 1). 
 
CSF results from an LP performed within 30 days of receiving their CrAg result (median 2.5 
days, interquartile range (IQR) 1-7) were available for 90/254 (35.4%) of asymptomatic CrAg-
positive patients and 78/173 (45.1%) of patients with headache only. Of note, no LP was 
recorded for 50/173 (28.9%) of patients who complained of a headache (and results were not 
available for the other 45 patients who were recorded to have had an LP). There was no 
significant difference in age or sex; however, CD4 count was lower in those who had an LP 
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performed compared to those who did not (median 22 cells/µL, IQR 7 – 39 vs. 27 cells/µL, IQR 
10-53, p=0.01) (Supplementary Table 1). 
 
On analysis of CSF, 31/90 (34%, 95% CI 25% - 45%) asymptomatic patients and 70/78 (90%, 
95% CI 81% - 96%) patients with headache only had evidence of meningeal infection with 
Cryptococcus. Having a headache compared with no symptoms was strongly predictive of 
concurrent cryptococcal meningitis (OR 16.7, 95% CI 7.1 – 39.0, p<0.001). There was no 
significant difference between patients with and without concurrent cryptococcal meningitis in 
terms of age (median, 37 vs. 39 years, p=0.24) or sex (male, 53% vs. 44%, p=0.3) although CD4 
counts were lower in those with concurrent cryptococcal meningitis (median 19 (IQR 5-35) vs. 
25 (10-42) cells/µl, p=0.06).  
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Thirty-seven (41%) of the 90 asymptomatic patients with CSF results, and 25 (32%) of the 78 
with headache only had stored samples available for blood CrAg titer analysis. Patients from 
whom blood samples were available were not significantly different to those without in terms of 
age, sex or CD4 count (p≥0.05) (Supplementary Table 1). Titers ranged from <5 to 2560 
(median 40, IQR 10-160) in those with no evidence of meningeal involvement, and 40 to 6.7x107 
(median 5120, IQR 1280-81920) in those with cryptococcal meningitis (Figure 2). Blood CrAg 
titer was significantly associated with cryptococcal meningitis in both asymptomatic patients 
(p<0.001) and patients with headache only (p=0.003) with area under the receiver operating 
characteristic curve of 0.93 (Figure 3). The optimal cut-off titer for predicting concurrent 
subclinical cryptococcal meningitis was >160, with sensitivity of 88.2% and specificity 82.1% 
(Table 1). A blood CrAg titer of >160 had an odds ratio of 34.5 for concurrent cryptococcal 
meningitis (95% CI 8.3-143.1, p<0.001) in the combined group and 11.2 (95% CI 2.3 - 54.6, 
p=0.002) in the asymptomatic group. 
 
The association between a blood titer of >160 and concurrent cryptococcal meningitis remained 
significant, even when adjusted for CD4 count (OR 38.4, 95% CI 8.0 – 185.0, p<0.001). 
 
All participants with symptom review and LP results available (n=168) were followed up for a 
median of 37 days (range 1-180 days).  Of those with available data, 89/107 (83%) were started 
on appropriate antifungal therapy; 44/45 (98%) of patients with cryptococcal meningitis 
received intravenous amphotericin B and oral fluconazole and 45/62 (73%) of those without 
received oral fluconazole.  
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Of 101 patients who had concurrent cryptococcal meningitis, 22 (22%) died and 6 (6%) were 
lost to follow up during the first 6 months, compared to 12 (18%) and 8 (12%) of 67 patients 
without cryptococcal meningitis. There was no association found between age, sex, CD4 count, 
CrAg titer, headache or ART status, and risk of death. However, receipt of any antifungal agent 
(amphotericin B, fluconazole or a combination) was found to be protective (HR 0.20, 95% CI 
0.08 – 0.49, p<0.001). When adjusting for receipt of antifungal therapy, the HR for death in 
those with concurrent cryptococcal meningitis was 2.00 (95% CI 0.83-4.78, p=0.12) in 
asymptomatic patients (Figure 4) and 1.82 (95% CI 0.88-3.79, p=0.11) in the combined cohort.  
There remained no significant association between CrAg titer and risk of mortality (HR 1.58, 
95% CI 0.57 – 4.36, p=0.38). 
 
Discussion 
More than a third of CrAg-positive patients with no signs or symptoms of meningitis, and 90% 
of those complaining of a headache only, had evidence of meningeal involvement on CSF 
analysis. In both groups, higher blood CrAg titers were associated with an increased risk of 
concurrent cryptococcal meningitis. A cut-off of >160 had moderate sensitivity (88.2%) and 
specificity (82.1%) for predicting CNS disease; however, no single titer cut-off could distinguish 
between those with and without concurrent cryptococcal meningitis with 100% accuracy. 
 
Previous studies have found higher CrAg titers to be associated with subsequent cryptococcal 
meningitis and mortality with a titer of around >160 consistently indicating increased risk 
(Table 2). Apart from our study, limited evidence exists for an association between CrAg titer 
and concurrent cryptococcal meningitis in patients without symptoms or signs of meningitis, or 
complaining of a headache only. Where CrAg-positive patients have received LPs following 
screening, the prevalence of concurrent cryptococcal meningitis is 25%-78%, with increased 
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risk in those with higher blood CrAg titers(10,13,19,21). However, many of these studies 
include symptomatic as well as asymptomatic patients. Our study established a significant risk 
of subclinical concurrent cryptococcal meningitis, which was associated with higher blood CrAg 
titers. This finding is important for informing management of CrAg-positive patients identified 
through the expansion of screening programmes worldwide. 
 
In our study, LPs were offered at the discretion of patients’ health practitioners, who may have 
elicited different signs and symptoms from patients than those recorded by study nurses. This 
may have led to an overestimation of the burden of concurrent cryptococcal meningitis, and a 
stronger association with headache than has been previously observed, since LPs would have 
been more likely offered to patients for whom there was a greater degree of suspicion of 
cryptococcal meningitis, and for patients admitted to health facilities where LPs were readily 
available. Patients who received LPs had lower CD4 counts than those who did not (22 vs. 27 
cells/µL). Of note, the proportion of patients with subclinical cryptococcal meningitis observed 
was similar to proportions reported in previous studies(10,13). 
 
Our study was also limited by the number of patients with available data, which did not reach 
the required sample size for survival analysis and may explain the lack of significant association 
between concurrent cryptococcal meningitis or high CrAg titer and mortality, as previously 
described(1,17,20). Additionally, almost all patients who were diagnosed with cryptococcal 
meningitis and had available antifungal data received some amphotericin B, which may have 
reduced mortality in this group and those with a high blood CrAg titer. Other variables which 
are known to affect prognosis, but which were not available for analysis in this study, include 
the presence of cryptococcal immune reconstitution inflammatory syndrome (IRIS), adherence 
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to antifungal therapy, concomitant diseases, HIV viral load, CSF cell counts and LP opening 
pressure, as well as whether or not repeated LPs were performed. 
 
Despite these limitations, the results highlight a substantial risk of concurrent cryptococcal 
meningitis among patients who are found to be CrAg-positive on screening but lack symptoms 
and signs that typically lead clinicians to investigate for meningitis with an LP. Since patients 
with cryptococcal antigenemia, treated pre-emptively with fluconazole therapy,  have a 2.5-fold 
increased risk of death when compared to individuals with similar CD4 counts without 
cryptococcal antigenemia(8–11), a more aggressive approach to management should be 
considered. Where performing LPs is possible, these should be used routinely to investigate for 
cryptococcal meningitis in all CrAg-positive patients, even those without symptoms. However, 
experience suggests that only a minority of asymptomatic or mildly symptomatic patients are 
willing to undergo LP, even if carefully counselled. In this study, more than a quarter of CrAg-
positive patients with a headache did not have an LP performed, although concurrent 
cryptococcal meningitis was diagnosed in 90% of those who did. Alternatively, blood CrAg titer 
could be used to tailor patient management. Those with higher CrAg titres, perhaps identified 
with a semi-quantitative CrAg test, could be targeted for more intensive, but still feasible and 
sustainable, antifungal therapy.  Further work is required to determine whether such an 
approach could improve the outcomes of patients with cryptococcal antigenemia. 
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Table 1 Sensitivity and specificity at blood CrAg titer cut-off levels, tested by serial dilution method, for concurrent 
cryptococcal meningitis among patients with no symptoms or signs of meningitis and those complaining of a headache 
only (n=62) 
Blood CrAg titer cut-off 
for predicting 
concurrent 
cryptococcal meningitis 
Sensitivity  
(%, 95% CI) 
Specificity  
(%, 95% CI) 
>5 100 (89.7-100) 21.4 (8.3-41.0) 
>10 100 (89.7-100) 32.1 (15.8-52.4) 
>20 100 (89.7-100) 46.4 (27.5-66.1) 
>40 97.1 (84.7-99.9) 57.1 (37.2-75.5) 
>80 91.2 (76.3-98.1) 71.4 (51.3-86.8)  
>160 88.2 (72.5-96.7) 82.1 (63.1-93.9) 
>320 79.4 (62.1-91.3) 85.7 (67.3-96.0) 
>640 76.5 (58.8-89.3) 89.2 (71.8-97.7) 
>1280 70.6 (52.5-84.9) 96.4 (81.7-99.9) 
>2560 61.8 (43.6-77.8) 100 (87.7-100) 
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Table 2 Studies including an analysis of blood CrAg titer with cryptococcal meningitis and/or mortality 
Country Year Study design Association between 
blood CrAg titer and 
cryptococcal 
meningitis and/or 
mortality  
Notes Ref 
Association between blood CrAg titer and subsequent cryptococcal meningitis and/or mortality 
South Africa 2009 Retrospective 
analysis of CrAg 
titers (using Latex 
Agglutination, LA) on 
pre-ART blood 
samples from 46 
patients.  
Higher baseline titer 
associated with 
increased risk of 
mortality (p=0.02), 
subsequent cryptococcal 
meningitis (p=0.03) and 
relapse (all >512) 
within 1 year.  
No baseline LP 
performed. 
Symptoms unknown. 
(1) 
Tanzania 2015 Retrospective 
analysis of blood 
CrAg titers (using 
LFA) on pre-ART 
blood samples from 
21 asymptomatic 
patients. 
Titer of >160 associated 
with subsequent 
cryptococcal meningitis 
(adjusted OR, 4.83; 95% 
CI, 1.24–8.41; P = .008) 
within 1 year. 
3 patients with titers 
≤160 died of unknown 
causes. 
(11) 
Uganda 2016 Cluster randomized 
trial of CrAg screen 
and treat strategy. 
CrAg titers (LFA) on 
151 asymptomatic 
patients. 
Titer of ≥160 associated 
with subsequent 
cryptococcal meningitis 
(HR OR 9.2, 95% CI 
2.14-39.58, p<0.01) 
(unpublished data) 
Increased risk of 
death/subsequent 
cryptococcal 
meningitis if titer ≥160 
and CD4 ≤50. 
(20) 
Tanzania 2011 CrAg screening of all 
HIV positive hospital 
admissions. Serum 
CrAg titers (LFA) on 
17/333 CrAg-
positive patients. 
Higher titer associated 
with mortality 
(p=0.004). 
All symptomatic, 
15/17 had 
cryptococcal 
meningitis. 
(17) 
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Association between blood CrAg titer and concurrent cryptococcal meningitis 
Democratic 
Republic of 
Congo (DRC) 
1989 Cross-sectional study 
of 44 newly 
diagnosed HIV 
infected adults 
performing baseline 
blood and CSF CrAg 
titers (LA). 
Higher titers associated 
with increasing risk of 
concurrent cryptococcal 
meningitis (PPV 92% for 
titer >128). 
Concurrent 
cryptococcal 
meningitis present in 
29/44 (66%) CrAg-
positive patients. 
Symptoms unknown. 
(21) 
South Africa 2016 Prospective study 
implementing CrAg 
screen and treat. 
Blood CrAg titers 
(LFA) on 10 patients 
who had a baseline 
LP. 
Higher titers associated 
with concurrent 
cryptococcal meningitis 
No cryptococcal 
meningitis in patients 
with titers of <160. 
Concurrent 
cryptococcal 
meningitis present in 
4/10 (40%). 
Symptoms unknown. 
(10) 
Cambodia 2007 Cross-sectional study 
screening patients 
with CD4 ≤200 
cells/µL and 
performing LPs in all 
CrAg-positive 
patients (n=53). 
Median titer (LA) higher 
in those with than those 
without concurrent 
cryptococcal meningitis 
(2048 vs. 16, p<0.0001). 
Concurrent 
cryptococcal 
meningitis present in 
41/53 (78%).  
Most symptomatic.  
(19) 
Thailand 2010 Retrospective study 
performed blood 
CrAg titers (LA) on 
12 asymptomatic 
CrAg-positive 
patients who had 
baseline LPs. 
Higher CrAg titers in 
those with cryptococcal 
meningitis than those 
without (128-1024 vs. 
8-128). 
Concurrent subclinical 
cryptococcal 
meningitis in 3/12 
(25%). 
(13) 
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Figure Legends 
 
Figure 1 Flow-chart to show individuals included and excluded from studies 
Figure 1 Blood CrAg titres in A) asymptomatic CrAg-positive patients (n=37) B) minimally symptomatic CrAg-positive 
patients (n=25) and C) combined cohort of asymptomatic and minimally symptomatic patients (n=62) with and without 
concurrent cryptococcal meningitis 
Figure 2 Receiver operating characteristic curve for blood CrAg titre and cryptococcal meningitis among patients with 
no symptoms or signs of meningitis and those complaining of a headache only (n=62) 
Figure 3 Kaplan-Meier survival estimates in asymptomatic CrAg-positive patients, n=90 with subclinical cryptococcal 
meningitis and without subclinical cryptococcal meningitis. Abbreviations: HR, hazard ratio; cmcat, cryptococcal 
meningitis category; pos, positive; neg, negative. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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